Literature DB >> 14752575

Urinary tract infection: an update on imaging strategies.

Anne Paterson1.   

Abstract

Urinary tract infections (UTIs) are a common cause of morbidity in children. The distinction between upper and lower tract UTI is clinically difficult but important, as permanent renal damage can occur when the UTI involves the kidneys. Children with a history of UTI need investigated promptly and thoroughly. The goal of imaging in UTI is to aid in the diagnosis of acute pyelonephritis, to identify those children who are at high risk of developing permanent renal damage, and to confirm and monitor the presence of renal scarring. This article reviews the role of radiology in each of these aims.

Entities:  

Mesh:

Year:  2004        PMID: 14752575     DOI: 10.1007/s00330-003-2038-x

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  4 in total

1.  Resolution of cortical lesions on serial renal scans in children with acute pyelonephritis.

Authors:  Koray Agras; Hülya Ortapamuk; Seniha Naldöken; Altuğ Tuncel; Ali Atan
Journal:  Pediatr Radiol       Date:  2006-12-14

Review 2.  Work-up of Pediatric Urinary Tract Infection.

Authors:  Bogdana Schmidt; Hillary L Copp
Journal:  Urol Clin North Am       Date:  2015-08-04       Impact factor: 2.241

3.  Feasibility of superb microvascular imaging to detect high-grade vesicoureteral reflux in children with urinary tract infection.

Authors:  Hee Kyung Kim; Sara O'Hara; Bo-Kyung Je; Steven J Kraus; Paul Horn
Journal:  Eur Radiol       Date:  2017-07-28       Impact factor: 5.315

4.  Ureteral dilatation detected in magnetic resonance imaging predicts vesicoureteral reflux in children with urinary tract infection.

Authors:  Norihiro Murakami; Jun-Ichi Kawada; Azumi Watanabe; Toshinao Arakawa; Takamasa Kano; Takako Suzuki; Ryo Tanaka; Daiei Kojima; Yoshihiko Kawano; Shin Hoshino; Hideki Muramatsu; Yoshiyuki Takahashi; Yoshiaki Sato; Masashi Koyama; Jun Natsume
Journal:  PLoS One       Date:  2018-12-21       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.